CoChat

Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma

Open access
Pinter, Matthias, Weinmann, Arndt, Wörns, Marcus-Alexander, Hucke, Florian, Bota, Simona, Marquardt, Jens U, Duda, Dan G, Jain, Rakesh K, Galle, Peter R, Trauner, Michael, Peck-Radosavljevic, Markus, Sieghart, Wolfgang · 2017 · United European Gastroenterology Journal
Cited by 55

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BackgroundInhibition of the renin–angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies. ObjectiveThe objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC). MethodsPatients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses. ResultsIn the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo); p = 0.014) and remained a significant prognostic factor upon multivariate analysis (HR = 0.6; 95% CI 0.4–0.9; p = 0.011). In subgroup analysis, patients treated with sorafenib plus RASi had better median OS (19.5 mo) compared to those treated with either sorafenib (10.9 mo) or RASi (9.7 mo) alone (p = 0.043). The beneficial effect of RASi on survival was confirmed in the Mainz cohort (n = 76).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2050640617695698

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 55

Metadata

Authors
Pinter, M., Weinmann, A., Wörns, M.-A., Hucke, F., Bota, S., Marquardt, J. U., Duda, D. G., Jain, R. K., Galle, P. R., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W.
Venue
United European Gastroenterology Journal
Publisher
Wiley
Published
2017-02-26
Volume
5
Issue
7
Pages
987-996
ISSN
  • 2050-6406 (ISSN-L)
  • 2050-6414
OpenAlex
W2592981965
Cited by
55
References
8
FWCI
4.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. https://app.cochat.ai/papers/10.1177/2050640617695698
The paper
Pinter, M., Weinmann, A., Wörns, M.-A., Hucke, F., Bota, S., Marquardt, J. U., Duda, D. G., Jain, R. K., Galle, P. R., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2017). Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterology Journal. https://doi.org/10.1177/2050640617695698

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.